Tag: AFib

VOLTA MEDICAL expands its hospital network in France as part of an international multicenter study with its VX1 artificial intelligence software in cardiology

For the treatment, in the operating room, of atrial fibrillation, the most complex and most common arrhythmia in the world 11 French research centers have already joined the study in 2021 The first results will be published in Q3 2023 MARSEILLE, France – ( BUSINESS WIRE ) – Volta Medical, an innovative […]

ABBOTT’S AMPLATZER™ AMULET™ DEVICE APPROVED BY FDA TO TREAT PEOPLE WITH ATRIAL FIBRILLATION AT RISK OF STROKE

– Amulet is the first and only minimally invasive treatment option to offer immediate closure of the left atrial appendage (LAA), so blood-thinning medication isn’t needed following implantation – The device helps to prevent blood clots from forming and leaving the LAA, reducing the risk of stroke in patients with […]

Gencaro Atrial Fibrillation Phase 2B Results Selected for Publication in Circulation: Arrhythmia and Electrophysiology

Analysis in full patient cohort shows Gencaro effect compared to standard of care In the GENETIC-AF entire cohort of heart failure patients treated with Gencaro, compared to patients treated with metoprolol succinate (TOPROL-XL), experienced: a 36% reduction in cumulative atrial fibrillation burden with a 55% reduction in daily atrial fibrillation […]

Ablacon Announces Martin Grasse as CEO and Clinical Study Progress

MENLO PARK, Calif., June 22, 2021 /PRNewswire/ — Ablacon, Inc., developer of an advanced mapping system to guide the treatment of atrial fibrillation (AF), announced today that is has promoted Martin Grasse to the position of Chief Executive Officer. Former CEO Duke Rohlen will continue with the company as Executive Chairman. “Marty has demonstrated exceptional leadership capabilities […]

Abbott Seeks Better Treatment Options for Patients with Both Atrial Fibrillation and Heart Failure with New Trial

– A new, first-of-its-kind study known as TAP-CHF leverages expertise across Abbott’s cardiovascular portfolio to optimize treatment for patients suffering from both AFib and heart failure – The trial will utilize Abbott technology including cardiac ablation and sensors to monitor for both pulmonary artery pressure and abnormal heartbeats – Historically, […]

AtriCure’s EPi-Sense System Approved by FDA for Treatment of Long-Standing Persistent Afib Patients

FDA approval results in the only label of its kind for more than 3 million patients in the United States, significantly expanding AtriCure’s addressable market Superiority trial showed a 29% difference in effectiveness at 12 months and a 35% difference in effectiveness at 18 months for long-standing persistent Afib patients. Study […]

Milestone Pharmaceuticals Announces First Patient Enrolled in the ReVeRA Study, its Phase 2 Trial of Etripamil in Atrial Fibrillation and Rapid Ventricular Rate

MONTREAL and CHARLOTTE, N.C., March 29, 2021 /PRNewswire/ — Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced the first patient has been enrolled in its Phase 2 proof-of-concept study of etripamil nasal spray for the Reduction of Ventricular Rate in patients experiencing Atrial fibrillation and rapid ventricular rate (AFib-RVR), […]

BioSig Awarded U.S. Patent Claims for the Noise-Filtering Methods for its Signal Processing Technology

Westport, CT, March 30, 2021 (GLOBE NEWSWIRE) — Claims address computer-implemented systems and methods for filtering noise from input cardiac signals using its PURE EP™ technology designed to elevate treatments for cardiac arrhythmias Atrial fibrillation is the most common arrhythmia type, affecting over 6 million people in the U.S. and causing […]

Medtronic Announces First Procedures in Pivotal Trial to Evaluate Novel Ablation Technology in Treating Atrial Fibrillation

Study Will Determine the Safety and Effectiveness of Pulsed Electrical Fields to Interrupt Irregular Heart Rhythms DUBLIN, March 4, 2021 /PRNewswire/ — Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the first procedures in the investigational device exemption (IDE) pivotal trial to evaluate the PulseSelect™ Pulsed Field Ablation (PFA) System, a […]